Hemorrhage Countermeasure Evaluation Capabilities RFI

The Defense Advanced Research Projects Agency (DARPA) is seeking input from industry and academia regarding capabilities for providing independent verification and validation, clinical trial, and commercialization support for hemorrhage countermeasures. This Request for Information (RFI) aims to identify potential partners capable of providing third-party assessments of safety and efficacy of potential hemorrhage countermeasures and assisting in development strategies. The RFI focuses on testing and evaluating hemorrhage countermeasures and resuscitation products using synthetic or biosynthetic components. Respondents are requested to submit a white paper detailing their organization's experience, facilities, and overall approach to supporting the capabilities listed. Key areas of focus include preclinical evaluation, clinical trial support, technology commercialization, and program management. • Preclinical evaluation capabilities, including in vitro and in vivo studies • Clinical trial support, including Phase I and II clinical trials • Technology commercialization and transition support • Program management and key personnel • Rough Order of Magnitude (ROM) estimate for the full scope of capabilities